K. Hutchinson

发表

W. Pao, K. Hutchinson, Katherine E. Hutchinson, 2012, Nature Medicine.

A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

A. Iafrate, W. Pao, P. Massion, 2011, The Journal of molecular diagnostics : JMD.

MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis

Qingxia Chen, Peilin Jia, William Pao, 2014, Genome Biology.

Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.

K. Hutchinson, G. Rossato, B. Geoerger, 2019, The Lancet. Oncology.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

CBP/p300 drives the differentiation of Regulatory T cells through transcriptional and non-transcriptional mechanisms.

W. Jones, K. Hutchinson, J. Giltnane, 2019, Cancer research.

CCNE1 amplification is associated with poor prognosis in patients with triple negative breast cancer

Jeffrey H. Chuang, Yate-Ching Yuan, K. Hutchinson, 2019, BMC Cancer.

Optimization of Dosing for EGFR-Mutant Non–Small Cell Lung Cancer with Evolutionary Cancer Modeling

N. Socci, A. Viale, M. Ladanyi, 2011, Science Translational Medicine.

Clinically relevant genes and regulatory pathways associated with NRASQ61 mutations in melanoma through an integrative genomics approach

Peilin Jia, Zhongming Zhao, Wei Jiang, 2014, Oncotarget.

1-21-2019 CCNE 1 amplification is associated with poor prognosis in patients with triple negative breast cancer

Jeffrey H. Chuang, Yate-Ching Yuan, K. Hutchinson, 2019 .

Comprehensive genomic profiling of pancreatic acinar cell carcinomas identifies recurrent RAF fusions and frequent inactivation of DNA repair genes.

P. Stephens, R. Yelensky, W. Pao, 2014, Cancer discovery.

Targeted next-generation sequencing of DNA regions proximal to a conserved GXGXXG signaling motif enables systematic discovery of tyrosine kinase fusions in cancer

Zhongming Zhao, N. Socci, A. Viale, 2010, Nucleic acids research.

BRAF Fusions Define a Distinct Molecular Subset of Melanomas with Potential Sensitivity to MEK Inhibition

P. Stephens, W. Pao, J. Sosman, 2013, Clinical Cancer Research.

Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer.

Carlos L. Arteaga, Kyung-Min Lee, Melinda E. Sanders, 2017, Cancer research.

Entrectinib in children and young adults with solid or primary CNS tumors harboring NTRK, ROS1, or ALK aberrations (STARTRK-NG)

C. Pratilas, K. Hutchinson, G. Meneses‐Lorente, 2022, Neuro-oncology.

Abstract CT109: A phase I/Ib study evaluating GDC-0077 plus fulvestrant in patients withPIK3CA-mutant, hormone receptor-positive/HER2-negative breast cancer

K. Hutchinson, D. Juric, A. Italiano, 2020 .

Abstract P1-19-46: A phase Ib dose escalation study evaluating the mutant selective PI3K-alpha inhibitor GDC-0077 (G) in combination with letrozole (L) with and without palbociclib (P) in patients withPIK3CA-mutant HR+/HER2- breast cancer

K. Hutchinson, D. Juric, A. Italiano, 2020 .

The receptor tyrosine kinase ErbB3 maintains the balance between luminal and basal breast epithelium

C. Perou, K. Polyak, K. Hutchinson, 2011, Proceedings of the National Academy of Sciences.

Juliann Chmielecki with Evolutionary Cancer Modeling Small Cell Lung Cancer − Optimization of Dosing for EGFR-Mutant Non

N. Socci, A. Viale, M. Ladanyi, 2011 .

MYC and MCL1 Cooperatively Promote Chemotherapy-Resistant Breast Cancer Stem Cells via Regulation of Mitochondrial Oxidative Phosphorylation.

S. Fesik, H. Gómez, K. Hutchinson, 2017, Cell metabolism.

Multimodal immunogenomic biomarker analysis of tumors from pediatric patients enrolled to a phase 1-2 study of single-agent atezolizumab

Trevor J Pugh, T. Pugh, K. Hutchinson, 2023, Nature Cancer.

MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysis

Zhongming Zhao, P. Jia, W. Pao, 2014, Genome Biology.

Comprehensive Profiling of Poor-Risk Paired Primary and Recurrent Triple-Negative Breast Cancers Reveals Immune Phenotype Shifts

K. Hutchinson, D. Halligan, Yuan Yuan, 2019, Clinical Cancer Research.

An ERBB1-3 Neutralizing Antibody Mixture With High Activity Against Drug-Resistant HER2+ Breast Cancers With ERBB Ligand Overexpression

K. Hutchinson, A. Guerrero-Zotano, M. V. Estrada, 2017, Journal of the National Cancer Institute.

ER+ Breast Cancers Resistant to Prolonged Neoadjuvant Letrozole Exhibit an E2F4 Transcriptional Program Sensitive to CDK4/6 Inhibitors

K. Hutchinson, S. Michiels, A. Guerrero-Zotano, 2018, Clinical Cancer Research.

Cancer Biology and Signal Transduction a Meta-analysis of Somatic Mutations from next Generation Sequencing of 241 Melanomas: a Road Map for the Study of Genes with Potential Clinical Relevance

Junfeng Xia, Peilin Jia, William Pao, 2022 .

BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors.

Junfeng Xia, Peilin Jia, William Pao, 2012, Cancer discovery.

Multiple PIK3CA mutation clonality correlates with outcomes in taselisib + fulvestrant-treated ER+/HER2–, PIK3CA-mutated breast cancers

E. Sokol, T. Wilson, K. Hutchinson, 2023, Genome Medicine.

Comparison of PIK3CA Mutation Prevalence in Breast Cancer Across Predicted Ancestry Populations

E. Sokol, K. Hutchinson, J. Newberg, 2022, JCO precision oncology.

Optimizing the Sequence of Anti-EGFR–Targeted Therapy in EGFR-Mutant Lung Cancer

X. Chen, Zhongming Zhao, M. Ladanyi, 2014, Molecular Cancer Therapeutics.

ERBB activation modulates sensitivity to MEK1/2 inhibition in a subset of driver-negative melanoma

X. Chen, Zhongming Zhao, M. Berger, 2015, Oncotarget.

Epigenetic repression of STING by MYC promotes immune evasion and resistance to immune checkpoint inhibitors in triple negative breast cancer.

Carlos L. Arteaga, K. Hutchinson, V. Malladi, 2022, Cancer immunology research.

Melanoma BRAF Fusions—Response

P. Stephens, W. Pao, J. Sosman, 2014, Clinical Cancer Research.

Cobimetinib in Pediatric and Young Adult Patients with Relapsed or Refractory Solid Tumors (iMATRIX-cobi): A Multicenter, Phase I/II Study

K. Hutchinson, B. Geoerger, H. Toledano, 2022, Targeted Oncology.

Systematic screen for tyrosine kinase rearrangements identifies a novel C6orf204‐PDGFRB fusion in a patient with recurrent T‐ALL and an associated myeloproliferative neoplasm

Annette S. Kim, N. Socci, A. Viale, 2012, Genes, chromosomes & cancer.

ErbB3 downregulation enhances luminal breast tumor response to antiestrogens.

C. Perou, K. Hutchinson, J. Balko, 2013, The Journal of clinical investigation.

Association of FGFR1 with ERα Maintains Ligand-Independent ER Transcription and Mediates Resistance to Estrogen Deprivation in ER+ Breast Cancer

S. Cairo, K. Hutchinson, A. Guerrero-Zotano, 2017, Clinical Cancer Research.

Objective Radiographic Response to MEK Inhibitor Therapy in a Patient with a Metastatic Melanoma with a BRAF

Zhongming Zhao, J. Netterville, P. Jia, 2012 .

Updated entrectinib data in children and adolescents with recurrent or refractory solid tumors, including primary CNS tumors.

K. Hutchinson, A. Sabnis, A. Gajjar, 2020 .

Title: Association of FGFR1 with ER  maintains ligand-independent ER transcription and 1 mediates resistance to estrogen deprivation in ER+ breast cancer 2

S. Cairo, K. Hutchinson, J. Balko, 2017 .

Phase 1/1B trial to assess the activity of entrectinib in children and adolescents with recurrent or refractory solid tumors including central nervous system (CNS) tumors.

K. Hutchinson, G. Meneses‐Lorente, A. Sabnis, 2019, Journal of Clinical Oncology.

EGFR-Mutant Lung Adenocarcinomas Treated First-Line with the Novel EGFR Inhibitor, XL647, Can Subsequently Retain Moderate Sensitivity to Erlotinib

X. Chen, A. Viale, M. Kris, 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Genomic profiling of ER+ breast cancers after short-term estrogen suppression reveals alterations associated with endocrine resistance

L. Garraway, X. Mu, R. Yelensky, 2017, Science Translational Medicine.

Genetic Heterogeneity and Tissue-specific Patterns of Tumors with Multiple PIK3CA Mutations

E. Sokol, L. Cantley, K. Hutchinson, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

ER+, HER2− advanced breast cancer treated with taselisib and fulvestrant: genomic landscape and associated clinical outcomes

K. Hutchinson, N. Harbeck, Y. Im, 2023, Molecular oncology.